FINWIRES · TerminalLIVE
FINWIRES

標普稱,中東戰爭曠日持久將導致亞太地區銀行信貸損失增加1,800億美元。

By

-- 標普全球評級週三發布報告稱,在中東戰爭持續的負面情景下,未來兩年亞太地區銀行的信貸損失可能激增約1800億美元。 在此情境下,2026年和2027年兩年期信貸損失總額可能達到9,100億美元,而標普的基本情境預測為7,300億美元。 標普表示,在此情境下,信貸損失佔貸款總額的比例上升將對越南、印尼和印度造成最大衝擊。 在標普的基本情境下,由於銀行對中東的直接風險敞口較低,間接風險敞口也可控,因此受戰爭的影響較小。 信貸分析師加文·岡寧表示,在負面情境下,銀行可能會受到家庭、企業和政府部門的次要影響。 對航空、能源、化學和運輸等易受影響的企業部門曝險較大的銀行將受到更大的衝擊。 然而,標普預計,在目前評級水準下,即使面臨下行風險,銀行的緩衝能力也足以應付。 在標普評等的該地區400多家金融機構中,92%的評等展望為穩定,僅有2.9%的評等展望為負面。

Related Articles

Research

Mizuho Downgrades Adobe to Neutral From Outperform, Adjusts Price Target to $270 From $315

Adobe (ADBE) has an average rating of overweight and mean price target of $321.05, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$ADBE
US Markets

Organon Agrees to Be Acquired by Sun Pharmaceutical in $11.75 Billion Deal

Organon (OGN) shares spiked early Monday after the healthcare company agreed to be acquired by Indian pharmaceutical firm Sun Pharmaceutical Industries in an all-cash deal with an enterprise value of about $11.75 billion.Shareholders of Organon will receive $14 a share in cash under the terms of the transaction, the companies said in a joint statement on Sunday. Organon's stock jumped 15% in the most recent premarket activity."Following a comprehensive review of strategic alternatives, our board determined that this all-cash transaction offers compelling and immediate value to Organon stockholders," Organon Chief Executive Carrie Cox said in the statement. "We believe Sun Pharma is well positioned to support Organon's businesses, employees and patients globally."Organon, which focuses on women's health, was formed in 2021 following its separation from pharmaceutical giant Merck (MRK).The deal, which requires approval from regulators and clearance from Organon's shareholders, is expected to complete early next year."This transaction is a logical next step in strengthening Sun Pharma's global business," according to Sun Pharma Managing Director Kirti Ganorkar. "In addition, there is a scope for synergies including significant revenue upside opportunities to be realized over the coming years."Sun Pharma intends to fund the acquisition through a combination of available cash resources and committed financing from banks. The Indian company anticipates the transaction to allow it to enter the biosimilar market.For the year ended Dec. 31, Organon reported revenue of $6.22 billion and adjusted earnings before interest, taxes, depreciation and amortization of $1.91 billion. In February, the company said it expected revenue of $6.2 billion for the current year, while five analysts polled by FactSet estimate $6.15 billion.

$OGN
Research

Morgan Stanley Initiates StubHub Holdings at Equalweight With $8.25 Price Target

StubHub Holdings (STUB) has an average rating of overweight and mean price target of $12.95, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$STUB